Abstract:The E3 ubiquitin ligase adaptor speckle-type POZ protein (SPOP) is frequently dysregulated in prostate adenocarcinoma (PC), via either somatic mutations or mRNA downregulation, suggesting an important tumour suppressor function. To examine its physiologic role in the prostate epithelium in vivo, we generated mice with prostate-specific biallelic ablation of Spop. These mice exhibited increased prostate mass, prostate epithelial cell proliferation, and expression of c-MYC protein compared to littermate controls, and eventually developed prostatic intraepithelial neoplasia (PIN). We found that SPOPWT can physically interact with c-MYC protein and, upon exogenous expression in vitro, can promote c-MYC ubiquitination and degradation. This effect was attenuated in PC cells by introducing PC-associated SPOP mutants or upon knockdown of SPOP via short-hairpin-RNA, suggesting that SPOP inactivation directly increases c-MYC protein levels. Gene Set Enrichment Analysis revealed enrichment of Myc-induced genes in transcriptomic signatures associated with SPOPMT. Likewise, we observed strong inverse correlation between c-MYC activity and SPOP mRNA levels in two independent PC patient cohorts. The core SPOPMT;MYCHigh transcriptomic response, defined by the overlap between the SPOPMT and c-MYC transcriptomic programmes, was also associated with inferior clinical outcome in human PCs. Finally, the organoid-forming capacity of Spop-null murine prostate cells was more sensitive to c-MYC inhibition than that of Spop-WT cells, suggesting that c-MYC upregulation functionally contributes to the proliferative phenotype of Spop knock-out prostates. Taken together, our data highlight SPOP as an important regulator of luminal epithelial cell proliferation and c-MYC expression in prostate physiology, identify c-MYC as a novel bona fide SPOP substrate, and help explain the frequent inactivation of SPOP in human PC. We propose SPOPMT-induced stabilization of c-MYC protein as a novel mechanism that can increase total c-MYC levels in PC cells, in addition to amplification of c-MYC locus.

Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-associated Mutants.

Destruction of DDIT3/CHOP Protein by Wild-Type SPOP but Not Prostate Cancer-Associated Mutants

SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression

Molecular Interplay between AURKA and SPOP Dictates CRPC Pathogenesis via Androgen Receptor

Prostate Cancer-Associated Mutation in SPOP Impairs Its Ability to Target Cdc20 for Poly-Ubiquitination and Degradation.

Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover

SPOP Inhibits BRAF-dependent Tumorigenesis Through Promoting Non-Degradative Ubiquitination of BRAF

The diverse roles of SPOP in prostate cancer and kidney cancer

Prostate Cancer-associated SPOP Mutations Enhance Cancer Cell Survival and Docetaxel Resistance by Upregulating Caprin1-dependent Stress Granule Assembly.

Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer

SPOP mutations promote p62/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer

Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP–HIPK2 axis

SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway

Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation

Tumor Suppressor SPOP Mediates the Proteasomal Degradation of Progesterone Receptors (prs) in Breast Cancer Cells

USP54 is a potential therapeutic target in castration-resistant prostate cancer

Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer

LRP5 competes for SPOP binding to enhance tumorigenesis mediated by Daxx and PD-L1 in prostate cancer

SPOP point mutations regulate substrate preference and affect its function

SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein

Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4